0000000000339471

AUTHOR

N Elahi

showing 2 related works from this author

International prevalence and risk factors evaluation for drug-resistant Streptococcus pneumoniae pneumonia

2019

Objective: Streptococcus pneumoniae is the most frequent bacterial pathogen isolated in subjects with Community-acquired pneumonia (CAP) worldwide. Limited data are available regarding the current global burden and risk factors associated with drug-resistant Streptococcus pneumoniae (DRSP) in CAP subjects. We assessed the multinational prevalence and risk factors for DRSP-CAP in a multinational point-prevalence study. Design: The prevalence of DRSP-CAP was assessed by identification of DRSP in blood or respiratory samples among adults hospitalized with CAP in 54 countries. Prevalence and risk factors were compared among subjects that had microbiological testing and antibiotic susceptibility…

0301 basic medicineMaleStreptococcus pneumoniaantibiotic resistanceInternationalitysputum examinationbronchiectasisvery elderlyAntibioticsPrevalenceDrug resistancemedicine.disease_causeLogistic regressionGlobal HealthCommunity-Acquired Infections/epidemiologylung lavage0302 clinical medicineCommunity-acquired pneumoniaCost of IllnessRisk FactorsPrevalencedrug resistant Streptococcus pneumoniae pneumonia030212 general & internal medicineMicrobial drug resistantAged 80 and overadultinternational cooperationdrug effectMiddle Agedinfluenza vaccinationAnti-Bacterial Agentsantiinfective agentEuropeCommunity-Acquired InfectionsHospitalizationGlobal burden of diseaseStreptococcus pneumoniaeInfectious Diseasesrisk factorbacterium identificationFemalecommunity acquired infectioninfluenzaliver diseasepneumococcal vaccinationPneumococcal infectionhospitalizationmedicine.drugMicrobiology (medical)medicine.medical_specialtyAsiamedicine.drug_class030106 microbiologySettore MED/10 - Malattie Dell'Apparato RespiratorioArticleAnti-Bacterial Agents/pharmacology03 medical and health sciencesInternal medicineStreptococcus pneumoniaeDrug Resistance BacterialPneumonia Pneumococcal/epidemiologymedicineHumanscontrolled studyhumantetracyclineHospitalization/statistics & numerical dataAgedlevofloxacinnonhumanbusiness.industrydisease associationmicrobiologycommunity acquired pneumoniamacrolidePneumoniaasthmaSouth AmericaPneumonia Pneumococcalvaccinationmedicine.diseasemajor clinical studyantibiotic sensitivitypenicillin derivativePenicillinStreptococcus pneumoniae/drug effectsPneumoniablood examinationAfricaNorth Americamicrobiological examinationbusinessGlobal burden of disease; Microbial drug resistant; Pneumococcal infection; Pneumonia
researchProduct

Fluid challenges in intensive care: the FENICE study: a global inception cohort study

2015

Background: Fluid challenges (FCs) are one of the most commonly used therapies in critically ill patients and represent the cornerstone of hemodynamic management in intensive care units. There are clear benefits and harms from fluid therapy. Limited data on the indication, type, amount and rate of an FC in critically ill patients exist in the literature. The primary aim was to evaluate how physicians conduct FCs in terms of type, volume, and rate of given fluid; the secondary aim was to evaluate variables used to trigger an FC and to compare the proportion of patients receiving further fluid administration based on the response to the FC. Methods: This was an observational study conducted i…

MaleSoins intensifs réanimationmedicine.medical_treatmentCohort Studies; Female; Humans; Male; Middle Aged; Practice Patterns Physicians'; Critical Care; Fluid Therapy; Critical Care and Intensive Care MedicinePractice PatternsESICM Trial GroupCritical Care and Intensive Care MedicineRESPONSIVENESSCohort StudiesSeven-Day Profile PublicationMedicine and Health SciencesPractice Patterns Physicians'FENICE InvestigatorsCIRCULATORY SHOCKintensive careddc:617RENAL REPLACEMENT THERAPYMiddle Aged3. Good healthOF-THE-LITERATURESHOCKFemalelipids (amino acids peptides and proteins)Erratumintensive care fluid therapyfluidsLife Sciences & BiomedicineCRITICALLY-ILL PATIENTSHumanCohort studymedicine.medical_specialtyCritical CareHYDROXYETHYL STARCH 130/0.4MEDLINE1117 Public Health and Health ServicesNOfluid therapyCritical Care MedicineCIRCULATORYGeneral & Internal MedicineIntensive careAnesthesiologyPATIENTSmedicinecohort studyHumansRenal replacement therapyIntensive care medicineintensive care; fluids; cohort studyPhysicians'Science & TechnologyCRITICALLY-ILLbusiness.industrySeptic shockSEPTIC SHOCK1103 Clinical Sciences3126 Surgery anesthesiology intensive care radiologymedicine.diseaseEmergency & Critical Care MedicineARTERIAL-PRESSURESEVERE SEPSISClinical trialFluid TherapyObservational studyCohort Studiebusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyTASK-FORCE
researchProduct